Clinical Trials Logo
  1. Home
  2. Cancer
  3. NCT06306924
  4. Details
NCT06306924 Clinical Trial

UNC Metastatic Cancer Radiation Therapy Registry

Cancer Clinical Trial

Official title:
UNC Metastatic Cancer Radiation Therapy Registry

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT06306924
Other study ID # LCCC2303
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 21, 2024
Est. completion date May 2033

Study information
Verified date April 2024
Source UNC Lineberger Comprehensive Cancer Center
Contact Kadiata Toumbou
Phone (202) 569-3721
Email kadiata@email.unc.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this registry is to collect clinical data from participants attending UNC Hospitals who present with metastatic cancer and are evaluated to receive radiation therapy as part of their standard of care treatment. The goal of this study is to provide a foundation for studies designed to identify projects across the translational continuum related to metastatic cancer and radiation therapy treatment. The relevant clinical data will be linked to patient-reported outcomes (PROs) thus allowing for a unique and robust dataset. Ultimately, this registry will provide current and future studies with the ability to analyze the correlation of radiation therapy regimens with metastatic cancer outcomes.

Recruitment information / eligibility
Status Recruiting
Enrollment 2000
Est. completion date May 2033
Est. primary completion date May 2033
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Written informed consent was obtained to participate in the study and HIPAA Authorization for release of personal health information. Ability to understand and willingness to sign informed consent Diagnosed with or is suspected to have metastatic cancer. Age = 18 years at the time of consent. Evaluated to receive radiation therapy as part of their standard-of-care treatment plan. Exclusion Criteria: All participants must not meet any of the following exclusion criteria prior to enrollment to participate in this study: Any serious medical or psychiatric disorder that would interfere with the participant's ability to give informed consent.

Study Design

Related Conditions & MeSH terms

Intervention

Radiation:
• Radiation therapy
Subjects with metastatic cancer receive radiation therapy.

Locations
Country Name City State
United States Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill Chapel Hill North Carolina

Sponsors (1)
Lead Sponsor Collaborator
UNC Lineberger Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Clinical Data Clinical data and radiological assessments from participants with metastatic cancer receiving radiation therapy as a part of the standard of care will be collected. Up to 1 month
Secondary Patient reported outcomes (PRO) Patient reported outcomes (PRO) from participants will be collected at different time points. Baseline, 1 month, 3 months, 6 months, 9 months, and 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases

External Links